Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06153069
Other study ID # KY2023-715
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date November 1, 2023
Est. completion date November 2027

Study information

Verified date December 2023
Source Huashan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized controlled trial among subclinical tuberculosis patients aiming to assess whether the standard treatment duration can be shortened to 17 weeks or even 8 weeks without changing the current anti-tuberculosis drugs or dosages.


Description:

This study is a prospective, open-label, multicenter randomized controlled trial. The randomization process employs central stratified block randomization to balance biases across different centers, initially stratified according to each participating center. Considering that radiological findings are crucial factors influencing treatment outcomes, the study will group patients based on the presence or absence of lesions in pulmonary imaging. Subclinical tuberculosis patients included in the study will be randomly assigned in a 1:1 ratio to either the standard treatment group or the short-course treatment group. The standard treatment regimen consists of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E) for 8 weeks, followed by rifampicin and isoniazid for an additional 18 weeks. The short-course treatment group follows the same regimen as the standard treatment group for the initial 8 weeks, and subsequent continuation treatment is determined based on the presence of radiological manifestations. Subclinical tuberculosis patients with radiological lesions will receive daily rifampicin and isoniazid for 9 weeks, resulting in a total treatment duration of 17 weeks. Those without radiological lesions will not undergo further continuation treatment, with a total treatment duration of 8 weeks.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 556
Est. completion date November 2027
Est. primary completion date October 2025
Accepts healthy volunteers No
Gender All
Age group 14 Years to 80 Years
Eligibility Inclusion Criteria: - 1. Age between 14 to 80 years; - 2. Male or female; - 3. Weight between 40 to 80 kg; - 4. Willing to provide signed informed consent, or parental consent and participant assent. - 5. Individuals with respiratory tract specimen (including sputum/induced sputum/bronchoalveolar lavage fluid/lung tissue) smear/culture/rapid molecular tests-positive pulmonary tuberculosis; - 6. No tuberculosis related symptoms that could not be explained by other causes within 6 months before enrollment. Tuberculosis related symptoms includes cough for more than 2 weeks, expectoration, hemoptysis, fever, night sweats, and weight loss. - 7. Not received any anti-TB treatment in the past 6 months - 8. If non-menopausal woman, agree to use or have used effective contraception during treatment. Exclusion Criteria: - 1. Combined extrapulmonary tuberculosis; - 2. Patients with extensive lesion (extent of disease greater than 50% or cavity size greater than 4cm) ; - 3. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of the following: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones; - 4. Patients with impaired liver function (alanine transaminase [ALT], alkaline phosphatase [ALP] or total bilirubin [TBIL] more than 2 times the upper limit of normal) or combined with liver cirrhosis; - 5. Leucocyte is less than 3×10^9/L, or hemoglobin is less than 90g/L, or platelet is less than 100*10^9/L; - 6. Estimated Glomerular Filtration Rate (eGFR) is less than 60 mL/min/1.73m2 - 7. Known allergic or intolerant to any of the study drugs - 8. Can not take oral medications - 9. HIV antibody positive and AIDS patients - 10.Have optic neuritis, alcoholism, epilepsy, mental illness, diabetes mellitus with fundus lesions, porphyria, myasthenia gravis - 11.Pregnant or breast-feeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Short-course regimen
During the intensive phase (8 weeks), rifampicin =50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide =50kg 1000mg daily, 50-70kg 1500mg daily, >70kg 2000mg daily; ethambutol =50kg 750mg daily, >50kg 1000mg daily; All treatment is taken orally. During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin =50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.
Standard regimen
During the intensive phase (8 weeks), rifampicin =50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide =50kg 1000mg daily, 50-70kg 1500mg daily, >70kg 2000mg daily; ethambutol =50kg 750mg daily, >50kg 1000mg daily; All treatment is taken orally. During the continuation phase (18 weeks), rifampicin =50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.

Locations

Country Name City State
China Hangzhou Red Cross Hospital Hangzhou Zhejiang
China Huashan Hospital of Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Huashan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment success rate of the short-course regimen To compare the treatment success rate without relapse between the short-course regimen group and the standardized regimen group. Treatment outcomes will be classified into favourable outcome and unfavourable outcome. 78 weeks after treatment initiation
Secondary Treatment success rate of the short-course regimen To compare the treatment success rate without relapse between the short-course regimen group and the standardized regimen group. Treatment outcomes will be classified into favourable outcome and unfavourable outcome. 104 weeks after treatment initiation
Secondary Relapse rate during follow-up To compare the relapse rate between the short-course regimen group and the standardized regimen group. 78 weeks after treatment initiation
Secondary Culture conversion rate Percentage of participants found to be culture-negative at the end of intensive phase and the end of treatment phase 8 weeks after treatment initiation, the end of treatment
Secondary Median time to Sputum Culture Conversion Time from treatment initiation to the first of two consecutive negative sputum cultures without an intervening positive culture in liquid media 8-26 weeks after treatment initiation
Secondary The frequency of grade 3 or greater adverse events To compare the proportion of patients who experience grade 3 or greater adverse events (graded according to the Division of AIDS severity criteria for adverse events), during treatment or follow-up, on the experimental regimen when compared to the control regimen 8-26 weeks after treatment initiation
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2